Cargando…
A prospective randomised trial of radiation with or without oral and intravesical misonidazole for bladder cancer.
Patients with T2 grade 3 and T3 bladder cancer were randomised to be treated with radiation alone (NO MISO) or with radiation and misonidazole (PLUS MISO). Patients in both groups initially received 40 Gy in 2 Gy fractions (5/week). Patients in the NO MISO arm received a further 20 Gy in 2 Gy fracti...
Autores principales: | Abratt, R. P., Craighead, P., Reddi, V. B., Sarembock, L. A. |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group
1991
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1977474/ https://www.ncbi.nlm.nih.gov/pubmed/1931628 |
Ejemplares similares
-
A new approach to the use of misonidazole as a radiosensitizer of hypoxic tumour cells.
por: Abratt, R. P.
Publicado: (1982) -
The quantitative response of human tumours to radiation and misonidazole.
por: Ash, D. V., et al.
Publicado: (1979) -
In vitro metabolism of misonidazole.
por: Josephy, P. D., et al.
Publicado: (1981) -
Effect of misonidazole on radiation injury to mouse spinal cord.
por: Travis, E. L., et al.
Publicado: (1982) -
A Prospective Study of a Resorbable Intravesical Fiducial Marker for Bladder Cancer Radiation Therapy
por: Greer, Matthew D., et al.
Publicado: (2021)